Michael V. Callahan MD, DTM&H, MSPH

Dr. Michael Callahan is a Staff Physician at MGH in internal medicine and infectious disease, and a clinical subject matter expert for international clinical trials for the Assistant Secretary of Public Health Preparedness (ASPR) of the Dept. of Health and Human Services, Washington, DC.

Dr. Callahan has conducted federal-funded basic science and clinical research in tropical infectious disease, sepsis, and immune therapeutics since 1986. In 2004 he was recruited by the Defense Advanced Research Projects Agency (DARPA) to run the $260M Accelerated Manufacture of Pharmaceuticals program to protect against natural and intentional pandemics and antimicrobial resistance.

While at DARPA, Dr. Callahan initiated 8 programs, which developed FIH therapeutics, and launched 11 companies, three of which have exceeded $1B in revenues within 8-years. Dr. Callahan’s inventions include liposomal encapsulated antimicrobials, vesicle encapsulation of antimicrobials for steady plasma pK (for weeks), development of triose field stable monoclonal antibodies for tropical disease and cancer, FIHgene encoded protein therapies for endogenous, non- encoded immune protection. Dr. Callahan serves as President of Cellular Therapies at United Therapeutics Corporation.